This book fills a significant research gap in how to integrate quality of life data into relevant clinical care plans, and to broaden its applicability to pharmacoeconomic studies of antipsychotic medications and health policy decision-making. It also presents an argument for reformulating the concept of health-related quality of life in schizophrenia as a bio-psycho-social construct, which provides an opportunity to better explore the many factors underpinning the concept itself.